1
|
Siegel R, Ward E, Brawley O and Jemal A:
Cancer statistics, 2011: The impact of eliminating socioeconomic
and racial disparities on premature cancer deaths. CA Cancer J
Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
|
2
|
Llovet JM, Burroughs A and Bruix J:
Hepatocellular carcinoma. Lancet. 362:1907–1917. 2003. View Article : Google Scholar : PubMed/NCBI
|
3
|
Center MM and Jemal A: International
trends in liver cancer incidence rates. Cancer Epidemiol Biomarkers
Prev. 20:2362–2368. 2011. View Article : Google Scholar : PubMed/NCBI
|
4
|
Kim CM, Koike K, Saito I, Miyamura T and
Jay G: HBx gene of hepatitis B virus induces liver cancer in
transgenic mice. Nature. 351:317–320. 1991. View Article : Google Scholar : PubMed/NCBI
|
5
|
Koike K, Moriya K, Iino S, et al:
High-level expression of hepatitis B virus HBx gene and
hepatocarcinogenesis in transgenic mice. Hepatology. 19:810–819.
1994. View Article : Google Scholar : PubMed/NCBI
|
6
|
Bouchard MJ and Schneider RJ: The
enigmatic X gene of hepatitis B virus. J Virol. 78:12725–12734.
2004. View Article : Google Scholar : PubMed/NCBI
|
7
|
Seeger C and Mason WS: Hepatitis B virus
biology. Microbiol Mol Biol Rev. 64:51–68. 2000. View Article : Google Scholar : PubMed/NCBI
|
8
|
Gouas D, Shi H and Hainaut P: The
aflatoxin-induced TP53 mutation at codon 249 (R249S): Biomarker of
exposure, early detection and target for therapy. Cancer Lett.
286:29–37. 2009. View Article : Google Scholar : PubMed/NCBI
|
9
|
Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang
NJ and Harris CC: Mutational hotspot in the p53 gene in human
hepatocellular carcinomas. Nature. 350:427–428. 1991. View Article : Google Scholar : PubMed/NCBI
|
10
|
Shen HM and Ong CN: Mutations of the p53
tumor suppressor gene and ras oncogenes in aflatoxin
hepatocarcinogenesis. Mutat Res. 366:23–44. 1996. View Article : Google Scholar : PubMed/NCBI
|
11
|
Li M, Zhao H, Zhang X, et al: Inactivating
mutations of the chromatin remodeling gene ARID2 in hepatocellular
carcinoma. Nat Genet. 43:828–829. 2011. View Article : Google Scholar : PubMed/NCBI
|
12
|
Boyault S, Rickman DS, de Reyniès A, et
al: Transcriptome classification of HCC is related to gene
alterations and to new therapeutic targets. Hepatology. 45:42–52.
2007. View Article : Google Scholar
|
13
|
Zender L, Villanueva A, Tovar V, Sia D,
Chiang DY and Llovet JM: Cancer gene discovery in hepatocellular
carcinoma. J Hepatol. 52:921–929. 2010. View Article : Google Scholar : PubMed/NCBI
|
14
|
Huang J, Deng Q, Wang Q, et al: Exome
sequencing of hepatitis B virus-associated hepatocellular
carcinoma. Nat Genet. 44:1117–1121. 2012. View Article : Google Scholar : PubMed/NCBI
|
15
|
Gandevia B and Tovell A: Declaration of
Helsinki. Med J Aust. 2:320–321. 1964.PubMed/NCBI
|
16
|
Levrero M, De Laurenzi V, Costanzo A, Gong
J, Wang IY and Melino G: The p53/p63/p73 family of transcription
factors: Overlapping and distinct functions. J Cell Sci.
113:1661–1670. 2000.PubMed/NCBI
|
17
|
Laptenko O and Prives C: Transcriptional
regulation by p53: One protein, many possibilities. Cell Death
Differ. 13:951–961. 2006. View Article : Google Scholar : PubMed/NCBI
|
18
|
Cho Y, Gorina S, Jeffrey PD and Pavletich
NP: Crystal structure of a p53 tumor suppressor-DNA complex:
Understanding tumorigenic mutations. Science. 265:346–355. 1994.
View Article : Google Scholar : PubMed/NCBI
|
19
|
Rossetti S and Sacchi N: RUNX1: A MicroRNA
hub in normal and malignant hematopoiesis. Int J Mol Sci.
14:1566–1588. 2013. View Article : Google Scholar : PubMed/NCBI
|
20
|
Blyth K, Cameron ER and Neil JC: The RUNX
genes: Gain or loss of function in cancer. Nat Rev Cancer.
5:376–387. 2005. View
Article : Google Scholar : PubMed/NCBI
|
21
|
Meyers S, Downing JR and Hiebert SW:
Identification of AML-1 and the (8; 21) translocation protein
(AML-1/ETO) as sequence-specific DNA-binding proteins: The runt
homology domain is required for DNA binding and protein-protein
interactions. Mol Cell Biol. 13:6336–6345. 1993.PubMed/NCBI
|
22
|
Miyagawa K, Sakakura C, Nakashima S, et
al: Down-regulation of RUNX1, RUNX3 and CBFbeta in hepatocellular
carcinomas in an early stage of hepatocarcinogenesis. Anticancer
Res. 26:3633–3643. 2006.PubMed/NCBI
|
23
|
Yamaoka K, Saharinen P, Pesu M, Holt VE
III, Silvennoinen O and O'Shea JJ: The Janus kinases (Jaks). Genome
Bio1. 5:2532004. View Article : Google Scholar
|
24
|
Pesu M, Laurence A, Kishore N, Zwillich
SH, Chan G and O'Shea JJ: Therapeutic targeting of Janus kinases.
Immunol Rev. 223:132–142. 2008. View Article : Google Scholar : PubMed/NCBI
|
25
|
Elliott NE, Cleveland SM, Grann V, Janik
J, Waldmann TA and Davé UP: FERM domain mutations induce gain of
function in JAK3 in adult T-cell leukemia/lymphoma. Blood.
118:3911–3921. 2011. View Article : Google Scholar : PubMed/NCBI
|